Journey Medical (DERM) Revenue & Revenue Breakdown
Journey Medical Revenue Highlights
Latest Revenue (Y)
$56.13M
Latest Revenue (Q)
$15.01M
Main Segment (Y)
Qbrexza
Journey Medical Revenue by Period
Journey Medical Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $56.13M | -29.11% |
| 2023-12-31 | $79.18M | 7.48% |
| 2022-12-31 | $73.67M | 16.69% |
| 2021-12-31 | $63.13M | 41.78% |
| 2020-12-31 | $44.53M | 27.52% |
| 2019-12-31 | $34.92M | -17.52% |
| 2018-12-31 | $42.34M | 832.37% |
| 2017-12-31 | $4.54M | -79.89% |
| 2016-12-31 | $22.59M | 209.38% |
| 2015-12-31 | $7.30M | - |
| 2014-12-31 | $7.30M | - |
Journey Medical generated $56.13M in revenue during NA 2024, up -29.11% compared to the previous quarter, and up 160.75% compared to the same period a year ago.
Journey Medical Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | $15.01M | 14.23% |
| 2025-03-31 | $13.14M | -3.53% |
| 2024-12-31 | $13.62M | -6.90% |
| 2024-09-30 | $14.63M | -1.52% |
| 2024-06-30 | $14.86M | 14.01% |
| 2024-03-31 | $13.03M | -14.60% |
| 2023-12-31 | $15.26M | -55.83% |
| 2023-09-30 | $34.54M | 101.14% |
| 2023-06-30 | $17.17M | 40.60% |
| 2023-03-31 | $12.21M | -23.51% |
| 2022-12-31 | $15.97M | -0.93% |
| 2022-09-30 | $16.12M | -11.89% |
| 2022-06-30 | $18.29M | -21.48% |
| 2022-03-31 | $23.30M | 32.99% |
| 2021-12-31 | $17.52M | -10.67% |
| 2021-09-30 | $19.61M | 28.27% |
| 2021-06-30 | $15.29M | 42.63% |
| 2021-03-31 | $10.72M | -21.89% |
| 2020-12-31 | $13.72M | 45.26% |
| 2020-09-30 | $9.45M | 0.34% |
| 2020-06-30 | $9.41M | -11.85% |
| 2020-03-31 | $10.68M | -7.39% |
| 2019-09-30 | $11.53M | -82.69% |
| 2019-06-30 | $66.64M | 2617.99% |
| 2019-03-31 | $2.45M | 9.32% |
| 2018-12-31 | $2.24M | 212.83% |
| 2018-09-30 | $717.00K | -98.17% |
| 2018-06-30 | $39.08M | 12970.23% |
| 2018-03-31 | $299.00K | -77.74% |
| 2017-12-31 | $1.34M | 25.98% |
| 2017-09-30 | $1.07M | - |
| 2017-06-30 | $1.07M | - |
| 2017-03-31 | $1.07M | -95.26% |
| 2016-12-31 | $22.47M | 18778.99% |
| 2016-09-30 | $119.00K | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | -100.00% |
| 2015-12-31 | $7.30M | - |
| 2015-09-30 | $7.30M | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | -100.00% |
| 2014-12-31 | $7.30M | - |
Journey Medical generated $15.01M in revenue during Q2 2025, up 14.23% compared to the previous quarter, and up 115.19% compared to the same period a year ago.
Journey Medical Revenue Breakdown
Journey Medical Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|
| Qbrexza | $25.11M | $25.41M | $26.71M | - |
| Amzeeq | $5.01M | $6.20M | $7.24M | - |
| Accutane | $19.41M | $20.17M | $18.37M | $10.05M |
| Zilxi | $1.64M | $1.96M | $2.27M | - |
| Targadox | - | $3.20M | $7.97M | $22.38M |
| Exelderm | - | $2.40M | $3.46M | $5.36M |
| Ximino | - | $287.00K | $4.96M | $8.25M |
| Other Branded Products | - | - | - | $37.00K |
| Qbrexa | - | - | - | $17.06M |
Latest
Journey Medical's latest annual revenue breakdown by segment (product or service), as of Dec 24: Qbrexza (49.08%), Accutane (37.92%), Amzeeq (9.79%), and Zilxi (3.21%).
Quarterly Revenue by Product
| Product/Service | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amzeeq | $879.00K | $1.10M | $1.51M | $1.54M | $1.21M | $755.00K | $1.35M | $1.16M | $1.26M | $3.47M | - | - | - | - |
| Zilxi | $256.00K | $426.00K | $443.00K | $558.00K | $369.00K | $273.00K | $422.00K | $554.00K | $555.00K | $741.00K | - | - | - | - |
| Qbrexza | $6.95M | $5.16M | $5.68M | $7.58M | $6.84M | $5.02M | $17.33M | $8.08M | $6.96M | $6.26M | - | - | - | - |
| Accutane | $3.40M | $3.65M | $3.87M | $4.00M | $5.72M | $5.82M | $14.59M | $5.58M | $4.14M | $4.12M | $5.20M | $4.91M | $4.38M | $3.53M |
| Targadox | - | - | - | - | - | - | - | - | $1.41M | $1.17M | $2.76M | $2.63M | $4.27M | $5.18M |
| Ximino | - | - | - | - | - | - | - | - | $1.18M | $1.77M | $1.03M | $967.00K | $1.97M | $2.86M |
| Exelderm | - | - | - | - | - | - | - | - | $445.00K | $1.00M | $1.31M | $704.00K | $1.04M | $1.37M |
| Qbrexa | - | - | - | - | - | - | - | - | - | - | $6.11M | $7.38M | $5.85M | $6.64M |
| Other Branded Products | - | - | - | - | - | - | - | - | - | - | - | $1.00K | $2.00K | $29.00K |
Latest
Journey Medical's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Qbrexza (60.54%), Accutane (29.58%), Amzeeq (7.66%), and Zilxi (2.23%).
Journey Medical Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| SGHT | Sight Sciences | $79.87M | $17.51M |
| DERM | Journey Medical | $56.13M | $15.01M |
| MXCT | MaxCyte | $38.63M | $10.39M |
| TLSI | TriSalus Life Sciences | $29.43M | $11.21M |
| PRE | Prenetics Global | $21.74M | $6.41M |
| PROF | Profound Medical | $10.68M | $2.62M |
| TNXP | Tonix Pharmaceuticals | $10.09M | $2.43M |
| SXTC | China SXT Pharmaceuticals | $1.97M | $939.58K |
| MCRB | Seres Therapeutics | - | - |
| BIOA | BioAge Labs | - | $1.45M |
| MIST | Milestone Pharmaceuticals | - | - |